MiR-190 Suppresses Breast Cancer Metastasis by Regulation of TGF-β-induced Epithelial-mesenchymal Transition

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2018 Mar 8

PMID 29510731

Citations 79

Authors

Yue Yu

Wei Luo

Zheng-Jun Yang

Jiang-Rui Chi

Yun-Rui Li

Yu Ding

Jie Ge

Xin Wang

Xu-Chen Cao

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is the most common cancer among women worldwide and metastasis is the leading cause of death among patients with breast cancer. The transforming growth factor-β (TGF-β) pathway plays critical roles during breast cancer epithelial-mesenchymal transition (EMT) and metastasis. SMAD2, a positive regulator of TGF-β signaling, promotes breast cancer metastasis through induction of EMT.

Methods: The expression of miR-190 and SMAD2 in breast cancer tissues, adjacent normal breast tissues and cell lines were determined by RT-qPCR. The protein expression levels and localization were analyzed by western blotting and immunofluorescence. ChIP and dual-luciferase report assays were used to validate the regulation of ZEB1-miR-190-SMAD2 axis. The effect of miR-190 on breast cancer progression was investigated both in vitro and in vivo.

Results: miR-190 down-regulation is required for TGF-β-induced EMT. miR-190 suppresses breast cancer metastasis both in vitro and in vivo by targeting SMAD2. miR-190 expression is down-regulated and inversely correlates with SMAD2 in breast cancer samples, and its expression level was associated with outcome in patients with breast cancer. Furthermore, miR-190 is transcriptionally regulated by ZEB1.

Conclusions: Our data uncover the ZEB1-miR-190-SMAD2 axis and provide a mechanism to explain the TGF-β network in breast cancer metastasis.

Citing Articles

RCE-IFE: recursive cluster elimination with intra-cluster feature elimination.

Kuzudisli C, Bakir-Gungor B, Qaqish B, Yousef M PeerJ Comput Sci. 2025; 11:e2528.

PMID: 40062294 PMC: 11888879. DOI: 10.7717/peerj-cs.2528.

Natural and Synthetic Progestins Increase Transcriptional Expression of primiR-190 and primiR-199 in T47D Breast Cancer Cells: A Preliminary Study.

Porter I, Berko H, Mafuvadze B Cureus. 2025; 17(1):e78293.

PMID: 40026926 PMC: 11872145. DOI: 10.7759/cureus.78293.

Identification of Molecular Subtypes and Prognostic Features of Breast Cancer Based on TGF-β Signaling-related Genes.

Qu J, Wang M, Gao Y, Zhang H Cancer Inform. 2025; 24:11769351251316398.

PMID: 39902175 PMC: 11789128. DOI: 10.1177/11769351251316398.

Integrating RNA-seq and scRNA-seq to explore the prognostic features and immune landscape of exosome-related genes in breast cancer metastasis.

Huang G, Yu Y, Su H, Gan H, Chu L Ann Med. 2025; 57(1):2447917.

PMID: 39847423 PMC: 11758802. DOI: 10.1080/07853890.2024.2447917.

Integrated miRNA Signatures: Advancing Breast Cancer Diagnosis and Prognosis.

Samara M, Thodou E, Patoulioti M, Poultsidi A, Thomopoulou G, Giakountis A Biomolecules. 2024; 14(11).

PMID: 39595529 PMC: 11591846. DOI: 10.3390/biom14111352.

References

De Craene B, Berx G . Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13(2):97-110. DOI: 10.1038/nrc3447. View

Chu H, Cheng C, Chou W, Hu L, Wang H, Hsiung C . A novel estrogen receptor-microRNA 190a-PAR-1-pathway regulates breast cancer progression, a finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis. Hum Mol Genet. 2013; 23(2):355-67. DOI: 10.1093/hmg/ddt426. View

Nassar F, Nasr R, Talhouk R . MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther. 2016; 172:34-49. DOI: 10.1016/j.pharmthera.2016.11.012. View

DAmato N, Rogers T, Gordon M, Greene L, Cochrane D, Spoelstra N . A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res. 2015; 75(21):4651-64. PMC: 4631670. DOI: 10.1158/0008-5472.CAN-15-2011. View

Jia W, Yu T, An Q, Yang H, Zhang Z, Liu X . MicroRNA-190 regulates FOXP2 genes in human gastric cancer. Onco Targets Ther. 2016; 9:3643-51. PMC: 4920243. DOI: 10.2147/OTT.S103682. View

Lin R, Lin Y, Chen J, Kuo H, Chen Y, Diccianni M . microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res. 2010; 70(20):7841-50. PMC: 4095771. DOI: 10.1158/0008-5472.CAN-10-0970. View

Massague J . TGFbeta in Cancer. Cell. 2008; 134(2):215-30. PMC: 3512574. DOI: 10.1016/j.cell.2008.07.001. View

Perdigao-Henriques R, Petrocca F, Altschuler G, Thomas M, Le M, Tan S . miR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes. Oncogene. 2015; 35(2):158-72. DOI: 10.1038/onc.2015.69. View

Almog N, Briggs C, Beheshti A, Ma L, Wilkie K, Rietman E . Transcriptional changes induced by the tumor dormancy-associated microRNA-190. Transcription. 2013; 4(4):177-91. PMC: 3977918. DOI: 10.4161/trns.25558. View

10.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

11.

De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I . miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res. 2011; 17(24):7684-92. PMC: 4008338. DOI: 10.1158/1078-0432.CCR-11-0610. View

12.

Cantelli G, Crosas-Molist E, Georgouli M, Sanz-Moreno V . TGFΒ-induced transcription in cancer. Semin Cancer Biol. 2016; 42:60-69. PMC: 6137079. DOI: 10.1016/j.semcancer.2016.08.009. View

13.

Yu Y, Zhao Y, Sun X, Ge J, Zhang B, Wang X . Down-regulation of miR-129-5p via the Twist1-Snail feedback loop stimulates the epithelial-mesenchymal transition and is associated with poor prognosis in breast cancer. Oncotarget. 2015; 6(33):34423-36. PMC: 4741463. DOI: 10.18632/oncotarget.5406. View

14.

Workman P, Aboagye E, Balkwill F, Balmain A, Bruder G, Chaplin D . Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010; 102(11):1555-77. PMC: 2883160. DOI: 10.1038/sj.bjc.6605642. View

15.

Feng Q, Zhang C, Lum D, Druso J, Blank B, Wilson K . A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nat Commun. 2017; 8:14450. PMC: 5316898. DOI: 10.1038/ncomms14450. View

16.

Jang M, Kim H, Kim E, Chung Y, Park S . Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. Hum Pathol. 2015; 46(9):1267-74. DOI: 10.1016/j.humpath.2015.05.010. View

17.

Lehmann W, Mossmann D, Kleemann J, Mock K, Meisinger C, Brummer T . ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat Commun. 2016; 7:10498. PMC: 4756710. DOI: 10.1038/ncomms10498. View

18.

Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V . MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell. 2014; 25(4):469-83. PMC: 3995091. DOI: 10.1016/j.ccr.2014.03.006. View

19.

Pan Q, Meng L, Ye J, Wei X, Shang Y, Tian Y . Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial-mesenchymal transition (EMT). Cancer Lett. 2017; 392:26-38. DOI: 10.1016/j.canlet.2017.01.039. View

20.

Shukla G, Singh J, Barik S . MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol. 2012; 3(3):83-92. PMC: 3315687. View